GlassScriptPhysician profile
Nicole Martinez
NPI 1013753383
$996.88
in general payments reported to CMS, 2019-2025
22 companies · $773 in 2025
The $773 reported for 2025 was more than what 81% of Nurse Practitioner providers received nationally (typical 2025 total: $174).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2024: $223 · 2025: $773.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $997.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $996.88 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Genzyme Corporation | $129.96 | 2025 | |
| Pfizer INC. | $90.08 | 2025 | |
| Janssen Biotech, INC. | $77.62 | 2024-2025 | Carvykti, Talvey, Tecvayli |
| Sobi, INC | $77.49 | 2024-2025 | |
| Jazz Pharmaceuticals INC. | $62.27 | 2025 | |
| Daiichi Sankyo INC. | $58.16 | 2024-2025 | Vanflyta |
| Kyowa Kirin, INC. | $46.75 | 2025 | |
| Incyte Corporation | $45.89 | 2025 | Monjuvi |
| Novartis Pharmaceuticals Corporation | $40.67 | 2024 | |
| Regeneron Healthcare Solutions, INC. | $40.57 | 2025 | Lynozyfic |
| Karyopharm Therapeutics INC. | $38.06 | 2025 | Xpovio |
| Genentech USA, INC. | $37.88 | 2024 | Venclexta |
| Lilly USA, LLC | $37.24 | 2025 | Jaypirca |
| Genmab U.S., INC. | $32.78 | 2024 | Epkinly |
| Geron Corporation | $27.48 | 2025 | Rytelo |
Show all 22 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Blueprint Medicines Corporation | $27.38 | 2024 | Ayvakit |
| Merck Sharp & Dohme LLC | $26.71 | 2025 | Prevymis |
| Invivyd INC | $22.69 | 2025 | Pemgarda |
| Servier Pharmaceuticals LLC | $20.51 | 2025 | |
| Sanofi-Aventis U.S. LLC | $20.16 | 2025 | |
| Azurity Pharmaceuticals, INC. | $18.60 | 2025 | Danziten |
| Beone Medicines USA, INC. | $17.93 | 2025 | Brukinsa |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Nicole Martinez listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.